Acetylsalicylic acid (aspirin) is often used for major and secondary prevention of cardiovascular ailments. Aspirin use is related to higher outcomes amongst COVID‐19 constructive sufferers. We hypothesized that aspirin use for major heart problems prevention might need a protecting impact on COVID‐19 susceptibility and illness length. We carried out a retrospective inhabitants‐based mostly cross‐sectional examine, using information from the Leumit Well being Companies database. The proportion of sufferers handled with aspirin was considerably decrease among the many COVID‐19‐constructive group, as in comparison with the COVID‐19‐unfavourable group (73 (11.03 %) vs. 1548 (15.77%); p=0.001). Aspirin use was related to decrease chance of COVID‐19 an infection, as in comparison with non‐customers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; p=0.041). Aspirin customers had been older (68.06 ± 12.79 vs. 56.63 ± 12.28 years of age; p<0.001), offered a decrease BMI (28.77±5.4 vs. 30.37±4.55; p<0.0189) and confirmed increased prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%) and COPD (11, 15.07%) than confirmed the aspirin non‐customers (151, 25.64%, p<0.001; 130, 22.07%, p<0.001; and 43, 7.3%, p=0.023, respectively). Furthermore, COVID‐19 illness length (thought of because the time between the primary constructive and second unfavourable COVID‐19 RT‐PCR check outcomes) amongst aspirin customers was considerably shorter, as in comparison with aspirin non‐customers (19.8±7.8 vs. 21.9± 7.9 p= 0.045). Amongst hospitalized COVID‐constructive sufferers, a better proportion of surviving topics had been handled with aspirin (20, 19.05%), versus 1 useless topic (14.29%), though this distinction was not vital (p=0.449). In conclusion, we noticed inverse affiliation between the chance of COVID‐19 an infection, illness length and mortality and aspirin use for major prevention.